2. Signaling Pathways
  3. Immunology/Inflammation
  4. PSMA

PSMA

Prostate-specific membrane antigen

PSMA is a transmembrane protein that anchores to the cell membrane through its transmembrane region and is mainly expressed in prostate epithelial cells but also exists in other tissues. PSMA exhibits glutamate-preferring carboxypeptidase activity that hydrolyzes polyglutamylated folic acid to release folic acid monomers. PSMA mediates the endocytosis on the cell surface. PSMA acts as an angiogenesis marker in cancer cells. PSMA can be used as a diagnostic marker for prostate cancer, and for detection of invasiveness and metastatic ability of the tumor[1].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99239
    Rosopatamab
    		99.50%
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency.
    Rosopatamab
  • HY-125399
    PSMA-11
    		99.52%
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer.
    PSMA-11
  • HY-148761
    Zadavotide guraxetan
    		99.87%
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa).
    Zadavotide guraxetan
  • HY-W054292
    tert-Butyl-DCL
    		Inhibitor 99.93%
    Tert-Butyl-DCL is a PSMA inhibitor. Tert-Butyl-DCL Tert-Butyl-DCL can be used in the research of prostate cancer.
    tert-Butyl-DCL
  • HY-P99517
    Voxalatamab
    		Inhibitor 99.90%
    Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer.
    Voxalatamab
  • HY-P11591
    PDI2
    		Ligand
    PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
    PDI2
  • HY-181696
    EC0652
    EC0652 is a PSMA imaging agent with SPECT imaging capability. EC0652 can be used for the research of metastatic castration-resistant prostate cancer.
    EC0652
  • HY-180308
    Flotufolastat
    		Modulator
    Flotufolastat is a prostate-specific membrane antigen (PSMA) modulator. Flotufolastat is also a radiodiagnostic agent used in prostate cancer imaging. Flotufolastat can be used in research on prostate cancer and other cancers.
    Flotufolastat
  • HY-100199
    HUHS015
    		99.32%
    HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC50 of 0.67μM for PCA-1.
    HUHS015
  • HY-P9992
    Pelgifatamab
    		Inhibitor 99.884%
    Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer.
    Pelgifatamab
  • HY-158123
    PSMA binder-1
    		98.88%
    PSMA binder-1 is a ligand for PSMA and can be used to synthesize PSMA targeting molecule, such as Ac-PSMA-trillium.
    PSMA binder-1
  • HY-141860
    PSMA-Val-Cit-PAB-MMAE
    		99.52%
    PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer.
    PSMA-Val-Cit-PAB-MMAE
  • HY-117756
    Piflufolastat
    		99.49%
    Piflufolastat (DCFPYL) can be used for the preparation of piflufolastat F 18 (DCFPyL F-18). Piflufolastat F-18 (DCFPyL F-18) is an 18F-labeled imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA). Piflufolastat can be used for imaging of prostate cancer.
    Piflufolastat
  • HY-160893
    PSMA-azide
    		Ligand 99.43%
    PSMA-azide is a prostate-specific membrane antigen (PSMA) ligand. PSMA-azide inhibits PSMA-dependent NAAG (N-acetylaspartylglutamic acid) hydrolysis, with an IC50 of 9 nM and a Ki of 1 nM. PSMA-azide contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups.
    PSMA-azide
  • HY-153550
    PSMA-1007
    		99.44%
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-1007
  • HY-147287
    Glu-urea-Glu-NHS ester
    		99.51%
    Glu-urea-Glu-NHS ester is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu. Glu-urea-Glu-NHS ester can be used for synthesis of small-molecule prostate-specific membrane antigen (PSMA) inhibitors, imaging agents (such as PSMAi-PEG conjugates), and targeted drug delivery vehicles.
    Glu-urea-Glu-NHS ester
  • HY-P5990
    Prostate Specific Antigen Substrate
    		98.79%
    Prostate Specific Antigen Substrate is a prostate specific antigen (PSA) fluorescent substrate. Prostate Specific Antigen Substrate can be used for detect enzymatic activity of PSA.
    Prostate Specific Antigen Substrate
  • HY-148152A
    PSMA I&S TFA
    		98.22%
    PSMA I&S (TFA) is a precursor of the 99mTc-labeled PSMA-targeting ligand.
    PSMA I&S TFA
  • HY-P5290
    HYNIC-PSMA
    		98.67%
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research. HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-PSMA
  • HY-139840
    GCPII-IN-1
    		Inhibitor 99.83%
    GCPII-IN-1 (Compound 2) is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 can be used in the research of prostate cancer.
    GCPII-IN-1
Cat. No. Product Name / Synonyms Application Reactivity